iPSC-MSC-derived exosomes attenuate pulmonary fibrosis by inhibiting pulmonary fibroblast activation via delivery of TRIM31

Key Points

• Exosomes derived from iPSC-MSCs effectively reduce pulmonary fibrosis, leading to better lung function and less tissue damage.
• Exosome treatment resulted in a significant decrease in fibroblast activation, with reductions observed at 7 days post-treatment.
• The approach involves using iPSC-MSC-derived exosomes to target molecular pathways associated with pulmonary fibroblast activation.
• This work may enable new treatments for pulmonary fibrosis, though further studies are needed in clinical settings.